Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radioactive tracer aims to illuminate hidden prostate cancer

NCT ID NCT07236112

Diagnosis Sponsor: C Ray Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests TRDC002, a radioactive tracer that attaches to PSMA proteins on prostate cancer cells, to improve PET/CT imaging in patients whose cancer has returned or spread. Six adults with PSMA-positive recurrent or metastatic prostate cancer will receive a single dose of TRDC002 and undergo PET/CT scans. The goal is to find the best dose and timing for clear images, while also checking safety and how the tracer moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TRDC002 (a radioactive tracer using copper-64 to bind to PSMA proteins on prostate cancer cells)
What this could lead to
If successful, this could provide a more accurate imaging method to detect where prostate cancer has spread, helping doctors choose better treatments.
What could go wrong
This is a very early Phase 1 trial with only 6 participants, so results may not apply to all patients. The tracer may not clearly show all cancer spots, and there are unknown safety risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 6 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants with recurrence or metastasis of prostate cancer. * Participants with PSMA-positive lesions. * Participants must have adequate bone marrow and organ function. * Participants with an ECOG performance status of 0 or 1. Exclusion Criteria: * Any immunotherapy or biological therapy (including antibodies) targeting PSMA within 60 days prior to the day of randomization. * A superscan is observed in the baseline bone scan. * Concurrent serious (as determined by the Investigator) medical conditions * Participants with symptomatic brain metastases, meningeal metastases, or spinal cord compression.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • Shandong Cancer Hospital

    Jinan, Shandong, 250117, China

  • Union Hospital, Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.